{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:23:15Z","timestamp":1790500995252,"version":"4.1.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,18]]},"DOI":"10.18632\/oncotarget.16466","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T15:04:51Z","timestamp":1490972691000},"page":"48362-48374","source":"Crossref","is-referenced-by-count":14,"title":["A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole<i>versus<\/i>tamoxifen for breast cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Danyang Hospital of Nantong University, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Forman","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Howell","year":"2014","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"djv263","DOI":"10.1093\/jnci\/djv263","article-title":"Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In situ","volume":"107","author":"Hwang","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"4","doi-asserted-by":"publisher","first-page":"Cd000563","DOI":"10.1002\/14651858.CD000563.pub7","article-title":"Post-operative radiotherapy for ductal carcinoma in situ of the breast","author":"Wilcken","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/sj.bjc.6603945","article-title":"Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project","volume":"97","author":"Bishop","year":"2007","journal-title":"Br J Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/s0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fehrenbacher","year":"1999","journal-title":"Lancet"},{"key":"7","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Palmer","year":"2002","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1158\/1078-0432.ccr-06-1136","article-title":"The science of selective estrogen receptor modulators: concept to clinical practice","volume":"12","author":"Jordan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/s0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/nejm198812293192601","article-title":"Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women","volume":"319","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1988","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/jco.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Wolmark","year":"2012","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"George","year":"2011","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Goldstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Sterne","year":"2011","journal-title":"Bmj"},{"key":"15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Schunemann","year":"2008","journal-title":"Bmj"},{"key":"16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"Bmj"},{"key":"17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Laird","year":"1986","journal-title":"Control Clin Trials"},{"key":"18","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Haenszel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Sydes","year":"2007","journal-title":"Trials"},{"key":"20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Minder","year":"1997","journal-title":"Bmj"},{"key":"22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/s0140-6736(15)01168-x","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Hopkins","year":"2016","journal-title":"Lancet"},{"key":"23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-014-3155-8","article-title":"Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial","volume":"148","author":"Yamaguchi","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"24","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"von Euler","year":"2000","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.coc.0000047126.10522.f9","article-title":"Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study","volume":"26","author":"Puig-Gali","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/s0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Jones","year":"2016","journal-title":"Lancet"},{"key":"27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1470-2045(11)70373-4","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial","volume":"13","author":"Noguchi","year":"2012","journal-title":"Lancet Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"von Euler","year":"2000","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Eidtmann","year":"2009","journal-title":"N Engl J Med"},{"key":"30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/s1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Forbes","year":"2010","journal-title":"Lancet Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Sahmoud","year":"2002","journal-title":"Lancet"},{"key":"32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0960-0760(03)00350-9","article-title":"\u2018Arimidex\u2019 (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview","volume":"86","author":"Buzdar","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-010-0888-x","article-title":"Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study","volume":"121","author":"Ito","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0960-0760(03)00374-1","article-title":"Advanced breast cancer updates on anastrozole versus tamoxifen","volume":"86","author":"Nabholtz","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1470-2045(06)70948-2","article-title":"Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis","volume":"7","author":"Jakesz","year":"2006","journal-title":"Lancet Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0","article-title":"Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy","volume":"76","author":"Schuyler","year":"1995","journal-title":"Cancer"},{"key":"37","first-page":"223","article-title":"Long-term follow-up of in situ carcinoma of the breast","volume":"11","author":"Rilke","year":"1994","journal-title":"Semin Diagn Pathol"},{"key":"38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1995.13.2.513","article-title":"Use of tamoxifen for breast cancer: twenty-eight years later","volume":"13","author":"Hortobagyi","year":"1995","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1200\/jco.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Walsh","year":"2005","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/jco.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Bjelic-Radisic","year":"2011","journal-title":"J Clin Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.SABCS-09-1047","article-title":"Effect of body mass index on recurrence in hormone receptor positive early breast cancer\u2014a retrospective exploratory analysis from the ATAC trial","volume":"69","author":"Cuzick","year":"2009","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T02:57:00Z","timestamp":1658890620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":42,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2017,7,18]]}},"alternative-id":["16466","28415634"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16466","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}